RVSV Pseudotyped EBOV GP

Description:

• Related to: Filoviruses
• Applications: ELISA

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description: EBOV sGP, recombinant protein from mammalian cells.

Description: Pre-made over-expression lentivirus for expressing human target: G12V mutant of kRas. Except the point mutation, the sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_004985. It also contains a GFP-Puromycin dual selection marker.

Description: Pre-made inducible lentiviral particles for expressing human target: h VEGFA (alternative name: VPF; VEGF; MVCD1; MGC70609), with ORF sequence 100% matching to CDS region in NCBI ID: NM_001171626.1. Particles has GFP-Puromycin dual marker.

Description: Pre-made over-expression lentivirus for expressing human target: CXCL12 (chemokine (C-X-C motif) ligand 12), [alternative names: IRH; PBSF; SCYB12; SDF1; TLSF; TPAR1]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_199168.3. It also contains a GFP-Puromycin dual selection marker.

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description: Ebola glycoprotein (aa 1-647), recombinant protein from 293 cell culture.

Description: EBOV GPDTM, recombinant protein from Sf9 cells.

Description: EBOV GPDTM, recombinant protein from mammalian cells.

Description: Ebola virus (subtype Zaire, strain Mayinga 1976) Glycoprotein, recombinant protein.

Description: Ebola virus (subtype Zaire, strain Mayinga 1976) Glycoprotein, recombinant protein.

Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein.

Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein.

Description: Please contact Gentaur in order to receive the datasheet of the product.

Description: rREBOV GPDTM, recombinant protein from Sf9 cells.

Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein.

Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein.

Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein.

Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein.

Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein, recombinant protein.

Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein, recombinant protein.

Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein.

Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein.

Description: Ebola virus (subtype Sudan, strain Uganda-00) Glycoprotein, recombinant protein.

Description: Ebola virus (subtype Sudan, strain Uganda-00) Glycoprotein, recombinant protein.

Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein, recombinant protein.

Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein, recombinant protein.

Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein (Virion spike glycoprotein), recombinant protein.

Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein (Virion spike glycoprotein), recombinant protein.

Description: Ebola virus (subtype Zaire, strain Mayinga 1976) Glycoprotein, recombinant protein.

Description: Ebola virus (subtype Zaire, strain Mayinga 1976) Glycoprotein, recombinant protein.

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Staphylococcus
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description: EBOV, recombinant protein from E. coli.

Description: EBOV Virus-Like Particles, recombinant protein from Sf9 cells.

Description: Ebola virus (subtype Zaire, strain Mayinga 1976) Glycoprotein, recombinant protein.

Description: Ebola virus (subtype Zaire, strain Mayinga 1976) Glycoprotein, recombinant protein.

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Staphylococcus
• Applications: ELISA, WB

Description: Recombinant Ebola Zaire Nucleoprotein (NP), contains the C-terminal portion of the Ebola Zaire nucleoprotein. Molecular weight is 15 kDa.

Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Unconjugated. Tested in the following application: ELISA

Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Unconjugated. Tested in the following application: ELISA, WB; Recommended dilution: WB:1:500-1:5000

Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Unconjugated. Tested in the following application: ELISA

Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Unconjugated. Tested in the following application: ELISA

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA

Description: Ebola Zaire nucleoprotein, recombinant protein from E. coli.

Description: EBOV VP40, recombinant protein from E. coli.

Description: HIV Chimeric Recombinant protein containing C-terminal of gp120 and most of gp41, expressed in E. coli. MW 27.3 kDa, 1.00 mg/mL.

Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein, recombinant protein.

Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein, recombinant protein.

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: WB

Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is HRP conjugated. Tested in the following application: ELISA

Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is FITC conjugated. Tested in the following application: ELISA

Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Biotin conjugated. Tested in the following application: ELISA

Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is HRP conjugated. Tested in the following application: ELISA

Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is FITC conjugated. Tested in the following application: ELISA

Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Biotin conjugated. Tested in the following application: ELISA

Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is HRP conjugated. Tested in the following application: ELISA

Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is FITC conjugated. Tested in the following application: ELISA

Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Biotin conjugated. Tested in the following application: ELISA

Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is HRP conjugated. Tested in the following application: ELISA

Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is FITC conjugated. Tested in the following application: ELISA

Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Biotin conjugated. Tested in the following application: ELISA

Description: Antibody raised against GP repeat

Description: Lake Victoria marburg virus (strain Angola/2005) envelope glycoprotein, recombinant protein.

Description: VZV Glycoprotein, natural protein.

Description: The Spike (B.1.429 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.429 Variant Spike (Genbank Accession #QHD43416.1 with B.1.429 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.429 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.429 variant in a Biosafety Level 2 facility.Spike Mutations in B.1.429 Variant: S13I
W152C
L452R
D614G

Description: The Spike (B.1.429 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.429 Variant Spike (Genbank Accession #QHD43416.1 with B.1.429 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.429 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.429 variant in a Biosafety Level 2 facility.Spike Mutations in B.1.429 Variant: S13I
W152C
L452R
D614G

Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617 (Kappa, Delta lineage) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617 variant in a Biosafety Level 2 facility. 

Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617 (Kappa, Delta lineage) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617 variant in a Biosafety Level 2 facility.

Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.1 (also known as the Kappa Variant) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.1 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.617.1 Variant:G142DE154KL452RE484QD614GP681RQ1071H

Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.1 (also known as the Kappa Variant) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.1 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.617.1 Variant:G142DE154KL452RE484QD614GP681RQ1071H

Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.618 was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.618 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.618 Variant Spike (Genbank Accession #QHD43416.1 with B.1.618 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.618 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.618 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.618 Variant:Y145delH146delE484KD614G

Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.618 was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.618 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.618 Variant Spike (Genbank Accession #QHD43416.1 with B.1.618 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.618 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.618 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.618 Variant:Y145delH146delE484KD614G

Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2 (also known as the Delta Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility.

Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2 (also known as the Delta Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility.

Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).

Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).

Description: The VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) was produced by re-expression of VSV-G as the envelope glycoprotein using the VSV Delta G system in which VSV-G is deleted. The pseudovirions contain the firefly luciferase gene; therefore, the VSV-G mediated cell entry can be measured via luciferase activity. The VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) can be used as a positive control of transduction for other VSV pseudotypes containing the envelope glycoproteins of heterologous viruses in a Biosafety Level 2 facility.

Description: The VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) was produced by re-expression of VSV-G as the envelope glycoprotein using the VSV Delta G system in which VSV-G is deleted. The pseudovirions contain the firefly luciferase gene; therefore, the VSV-G mediated cell entry can be measured via luciferase activity. The VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) can be used as a positive control of transduction for other VSV pseudotypes containing the envelope glycoproteins of heterologous viruses in a Biosafety Level 2 facility.

Description: The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently measured via luciferase reporter activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ _x000D_

Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently measured via luciferase reporter activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ _x000D_

Description: The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

Description: Ebola virus BDBV (subtype Bundibugyo strain Uganda 2007) Small/secreted Glycoprotein (sGP), recombinant protein from HEK 293 cells with a polyhistidine tag at the C-terminus.

Description: Ebola virus BDBV (subtype Bundibugyo strain Uganda 2007) Small/secreted Glycoprotein (sGP), recombinant protein from HEK 293 cells with a polyhistidine tag at the C-terminus.

Description: Ebola virus BDBV (subtype Zaire strain Kikwit-95) Envelope Glycoprotein (GP) containing GP1 and GP2, recombinant protein from HEK 293 cells with a polyhistidine tag at the C-terminus.

Description: Ebola virus BDBV (subtype Zaire strain Kikwit-95) Envelope Glycoprotein (GP) containing GP1 and GP2, recombinant protein from HEK 293 cells with a polyhistidine tag at the C-terminus.

Description: HIV Chimeric Recombinant gp120 and gp41 (a.a. 485-631), recombinant protein from E. coli. MW 43 kDa, 2.70 mg/mL.

Description: Pre-made lentiviral particles expressing SV40 large T-antigen under suCMV promoter, containing GFP-puromycin fusion dual marker.

Description: Pre-made tet-inducible lentiviral particles expressing a human gene with a Blasticidin-RFP fusion marker (Dual selection). The expressed human gene, PBK, is fully sequence verified and matched to NCBI accession ID: NM_018492.2

Description: Pre-made tet-inducible lentiviral particles expressing a human gene with a GFP-Puromycin fusion marker (Dual selection). The expressed human gene, TERT, is fully sequence verified and matched to NCBI accession ID: NM_198253.2

Description: Pre-made over-expression lentivirus for expressing mouse target: VSIR V-set immunoregulatory receptor), [alternative names: Dies1; PD-1H; VISTA]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_028732.4. It contains a GFP-Puromycin dual selection marker.

Description: Pre-made over-expression lentivirus for expressing C-terminal His-Taggedhuman target: CD274 (6His) (human CD274 molecule), [alternative names: B7-H; B7H1; PD-L1; PDCD1L1; PDCD1LG1; PDL1]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_014143.3. It contains a GFP-Puromycin dual selection marker.

Description: Pre-made over-expression lentivirus for expressing human target: CD19 (human CD19 molecule), [alternative names: B4; CVID3]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_001178098.1. It contains a GFP-Puromycin dual selection marker.

Description: Pre-made over-expression lentivirus for expressing human target: SF3B1 (splicing factor 3b subunit 1), [alternative names: Hsh155; MDS; PRP10; PRPF10; SAP155; SF3b155]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_012433. It also contains a GFP-Puromycin dual selection marker.

Description: Pre-made over-expression lentivirus for expressing human target: SRSF2 (serine and arginine rich splicing factor 2), [alternative names: PR264; SC-35; SC35; SFRS2; SFRS2A; SRp30b]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_003016. It also contains a GFP-Puromycin dual selection marker.

Description: Pre-made over-expression lentivirus for expressing human target: U2AF1 (U2 small nuclear RNA auxiliary factor 1), [alternative names: FP793; RN; RNU2AF1; U2AF35; U2AFBP]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_001025203. It also contains a GFP-Puromycin dual selection marker.

Description: Pre-made over-expression lentivirus for expressing human target: ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2), [alternative names: U2AF1-RS2; U2AF1L2; U2AF1RS2; URP; ZC3H22]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_005089. It also contains a GFP-Puromycin dual selection marker.

Description: Pre-made over-expression lentivirus for expressing human target: RBM10 (RNA binding motif protein 10), [alternative names: DXS8237E; GPATC9; GPATCH9; S1-1; TARPS; ZRANB5]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_005676.4 . It also contains a GFP-Puromycin dual selection marker.

Description: Premade lentivirus natively over-express human AKR1C3 gene. It contains a GFP_Puromycin fusion dual marker.

Description: Premade lentivirus expressing human TERT gene under suCMV promoter, containing GFP-Puromycin fusion dual marker.

Description: Premade lentivirus expressing human TERT gene under EF1a promoter, containing GFP-Puromycin fusion dual marker.

Description: Premade lentivirus expressing Epstein Barr Virus' EBNA1 gene under EF1a promoter, containing GFP-Puromycin dual marker.

Description: Premade lentivirus expressing Epstein Barr Virus' EBNA2 gene under EF1a promoter, containing GFP-Puromycin dual marker.

Description: Premade lentivirus expressing HpV16 virus' E6 gene under EF1a promoter, containing GFP-Puromycin dual marker.

Description: Premade lentivirus expressing Adenovirus type 5's E1A gene under EF1a promoter, containing GFP-Puromycin dual marker.

Description: Premade lentivirus expressing human HOXA9 gene under EF1a promoter, containing GFP-Puromycin dual marker.

Description: Premade lentivirus expressing human Kras V12G mutant under EF1a promoter, containing GFP-Puromycin dual marker.

Description: Premade lentivirus expressing human CDK4 gene under EF1a promoter, containing GFP-Puromycin dual marker.

Description: Premade lentivirus expressing human cMyc gene under EF1a promoter, containing GFP-Puromycin dual marker.

Description: Please contact Gentaur in order to receive the datasheet of the product.

Description: Please contact Gentaur in order to receive the datasheet of the product.

Description: Please contact Gentaur in order to receive the datasheet of the product.

Description: Please contact Gentaur in order to receive the datasheet of the product.

Description: Please contact Gentaur in order to receive the datasheet of the product.

Description: Please contact Gentaur in order to receive the datasheet of the product.

Description: Please contact Gentaur in order to receive the datasheet of the product.